OR WAIT null SECS
Jill Murphy is Editor of Pharmaceutical Technology.
July 31, 2023
The new facility is set to utilize and extend SCG's capabilities in advanced cell therapy manufacturing and off-the-shelf human-induced Pluripotent Stem Cell (iPSC) technology.
July 28, 2023
The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025.
July 27, 2023
The partnership is an extension of the collaboration from AbbVie and Scripps Research that was formed in 2019, according to the press release.
In this episode of Drug Digest, Pharmaceutical Technology editors discuss what happens in the manufacturing space from a CDMO and a cell/gene therapy perspective.
July 18, 2023
The goal for Upperton is to become fully operational by Q4 of 2023 for development and non-GMP manufacturing and a target start of GMP operations in January 2024.
After the completion of the merger, the company is expected to operate under the name “Neurogene Inc."